Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer

Abstract excerpt

Substantial improvements in the early detection and treatment of breast cancer have led to improvements in survival, but breast cancer remains a significant cause of morbidity and mortality in women. In 2012, the mammalian target of rapamycin (mTOR) inhibitor everolimus was approved by the U.S. Food and Drug Administration for the treatment of advanced breast cancer in patients resistant to endocrine therapy....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to PI3K/AKT/mTOR signaling in cancer
• Share to Tuberous Sclerosis Complex Research